Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June [Yahoo! Finance]
LowReport
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June [Yahoo! Finance]
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
MediumReport
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
MediumReport
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.
LowReport
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: